Prof Christopher Porter - Researcher Profile

Christopher JH Porter

Address

Monash Institute of Pharmaceutical Sciences
381 Royal Parade

Contact Details

Tel: +61 3 990 39649

Fax: +61 3 9903 9649

Email: Chris.Porter@monash.edu


Biography

Taking drug compounds on the ride to absorption

Even highly potent drug candidates have limited practical utility if the drug is not well-absorbed. Professor Christopher Porter says low water solubility and poor target specificity present a significant challenge for drug development. Chris is researching the fundamentals of how drugs are absorbed and distributed to their sites of action, and aims to develop drug delivery systems to enhance their clinical utility.

Chris is Professor of Pharmaceutics at the Monash Institute of Pharmaceutical Sciences and Associate Dean of Research in the Faculty of Pharmacy and Pharmaceutical Sciences. Chris’ group works to address the poor oral absorption of drugs with intrinsically low water solubility, and to develop delivery systems to enhance the activity and reduce the toxicity of anti-cancer agents. 

Unfortunately, more than 50 per cent of drug candidates have low water solubility. Compounds such as this are poorly absorbed after oral administration since drugs must pass into solution in the fluids of the gastrointestinal tract before they can be absorbed. 

“The problem of poorly-water-soluble drugs is not insignificant because the properties that make drugs bind to receptors most effectively, and therefore that increase potency, simultaneously reduce solubility in water,” Chris explains. “That’s a problem if you want to give drugs orally. 

"However, we do know that the body has developed myriad systems to deal with the absorption of dietary fats and lipids, which have similar characteristics to many poorly-water-soluble drugs. Much of my research is about understanding the ways in which the body has evolved to deal with dietary lipids, and applying that understanding to improving the absorption of poorly water-soluble drugs.” 

A series of events in the gastrointestinal tract (GI tract) and the absorptive cells that line the GI tract promote the absorption of dietary lipids. 

“When we eat fat, a cascade of events is stimulated to help the body absorb those materials. For example, pancreatic enzymes are secreted to promote digestion and bile is secreted from the gall bladder. One of the functions of bile acids is to act like a detergent, solubilising the lipid digestion products and forming a reservoir that allows for very efficient absorption. When we co-administer a drug with lipids we can piggyback drug absorption onto the back of this natural lipid absorption process. We are currently attempting to develop in vitro models of this lipid digestion process to help us identify the ideal lipids with which to promote drug absorption.” 

Chris is also collaborating with Melbourne-based biotechnology company, Starpharma, to develop dendrimers into nanomedicines to better deliver drugs to their intended target. 

“Dendrimers are branched polymers that can be synthesised with almost infinite complexity but also with great precision and therefore provide an excellent vehicle for the delivery of drugs. With Starpharma we are exploring the utilisation of dendrimers to improve drug delivery in a number of ways, but perhaps the most interesting is the use of dendrimer-based drug delivery systems to improve anti cancer therapy. 

"By modifying the structure of these nanomaterials we can promote retention in the blood circulation for long periods of time after a single intravenous injection. Ultimately, this leads to accumulation in tumours, because the blood vessels that supply nutrients to tumours have quite permeable walls. In itself this is promising – but the challenge is to go one step further, and to add specific targeting agents to the surface of these nanomaterials in order to actively direct delivery to particular cell types. This is the area we are focussed on at the moment.”

Research & Supervision Interests

    • Oral drug delivery, bioavailability enhancement and lymphatic drug transport
    • Lipid-based formulation design and assessment
    • Drug interactions with intracellular binding proteins
    • Nanomedicines, in particular dendrimer-based drug delivery

Keywords

Lipid-based formulation design,, Nanomedicines, dendrimer-based drug delivery, , Oral drug delivery, bioavailability enhancement, , intracellular binding proteins,, lymphatic drug transport , polyethylen glycol; dendrimer; poly l-lysine; pharmacokinetics, biodistribution

Qualifications

PH.D IN PHARMACEUTICS
Institution: Nottingham University
Year awarded: 1992

Publications

Journal Articles

Kaminskas, L., McLeod, V., Kelly, B., Sberna, G., Boyd, B., Williamson, M., Owen, D., Porter, C., 2012, A comparison of changes to doxorubicin pharmacokinetics, antitumour activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems, Nanomedicine-Nanotechnology Biology And Medicine [P], vol 8, issue 1, Elsevier, Netherlands, pp. 103-111.

Kaminskas, L.M., McLeod, V.M., Porter, C.J., Boyd, B.J., 2012, Association of chemotherapeutic drugs with dendrimer nanocarriers: an assessment of the merits of covalent conjugation compared to noncovalent encapsulation, Molecular Pharmaceutics [P], vol 9, issue 3, American Chemical Society, USA, pp. 355-373.

Kaminskas, L.M., McLeod, V.M., Kelly, B.D., Cullinane, C.M., Sberna, G., Williamson, M., Boyd, B.J., Owen, D.J., Porter, C.J., 2012, Doxorubicin-conjugated PEGylated dendrimers show similar tumoricidal activity but lower systemic toxicity when compared to PEGylated liposome and solution formulations in mouse and rat tumour models, Molecular Pharmaceutics [P], vol 9, American Chemical Society, United States, pp. 422-432.

Van Speybroeck, M., Williams, H.D., Nguyen, T., Anby, M.U., Porter, C.J., Augustijns, P., 2012, Incomplete desorption of liquid excipients reduces the in vitro and in vivo performance of self-emulsifying drug delivery systems solidified by adsorption onto an inorganic mesoporous carrier, Molecular Pharmaceutics [P], vol 9, issue 9, American Chemical Society, Washington DC, USA, pp. 2750-2760.

Caliph, S.M., Trevaskis, N., Charman, W.N., Porter, C.J., 2012, Intravenous dosing conditions may affect systemic clearance for highly lipophilic drugs: implications for lymphatic transport and absolute bioavailability studies, Journal of Pharmaceutical Sciences [P], vol 101, issue 9, Wiley-Blackwell, Malden, Massachusetts USA, pp. 3540-3546.

Anby, M.U., Williams, H.D., McIntosh, M.P., Benameur, H., Edwards, G.A., Pouton, C.W., Porter, C.J., 2012, Lipid digestion as a trigger for supersaturation: evaluation of the impact of supersaturation stabilization on the in vitro and in vivo performance of self-emulsifying drug delivery systems, Molecular Pharmaceutics [P], vol 9, issue 9, American Chemical Society, USA, pp. 2063-2079.

Williams, H.D., Sassene, P.J., Kleberg, K., Bakala-N'Goma, J., Calderone, M., Jannin, V., Igonin, A., Partheil, A., Marchaud, D., Jule, E., Vertommen, J., Maio, M., Blundell, R., Benameur, H., Carriere, F., Mullertz, A., Porter, C.J., Pouton, C.W., 2012, Toward the establishment of standardized in vitro tests for lipid-based formulations, Part 1: Method parameterization and comparison of in vitro digestion profiles across a range of representative formulations, Journal of Pharmaceutical Sciences [P], vol 101, issue 9, Wiley-Blackwell, Malden, Massachusetts USA, pp. 3360-3380.

Williams, H.D., Anby, M.U., Sassene, P.J., Kleberg, K., Bakala-N'Goma, J., Calderone, M., Jannin, V., Igonin, A., Partheil, A., Marchaud, D., Jule, E., Vertommen, J., Maio, M., Blundell, R., Benameur, H., Carriere, F., Mullertz, A., Pouton, C.W., Porter, C.J., 2012, Toward the establishment of standardized in vitro tests for lipid-based formulations. 2. The effect of bile salt concentration and drug loading on the performance of type I, II, IIIA, IIIB, and IV formulations during in vitro digestion, Molecular Pharmaceutics [P], vol 9, issue 11, American Chemical Society, Washington DC, USA, pp. 3286-3300.

Trevaskis, N., Charman, W., Porter, C., 2011, Acute hypertriglyceridemia promotes intestinal lymphatic lipid and drug transport: a positive feedback mechanism in lipid and drug absorption, Molecular Pharmaceutics [P], vol 8, American Chemical Society, USA, pp. 1132-1139.

Kaminskas, L., McLeod, V., Sberna, G., Boyd, B., Owen, D., Porter, C., 2011, Capping methotrexate alpha-carboxyl groups enhances systemic exposure and retains the cytotoxicity of drug conjugated PEGylated polylysine dendrimers, Molecular Pharmaceutics [E], vol 8, American Chemical Society, USA, pp. 338-349.

Kaminskas, L., Kelly, B., McLeod, V., Sberna, G., Owen, D., Boyd, B., Porter, C., 2011, Characterisation and tumour targeting of PEGylated polylysine dendrimers bearing doxorubicin via a pH labile linker, Journal of Controlled Release [P], vol 152, Elsevier Science Publishers, The Netherlands, pp. 241-248.

Kaminskas, L., Boyd, B., Porter, C., 2011, Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties, Nanomedicine [P], vol 6, issue 6, Future Medicine, UK, pp. 1063-1084.

Kaminskas, L., McLeod, V., Porter, C., Boyd, B., 2011, Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance, Journal of Pharmaceutical Sciences [P], vol 11, John Wiley & Sons Inc, USA, pp. 5069-5077.

Trevaskis, N., Nguyen, G., Scanlon, M., Porter, C., 2011, Fatty acid binding proteins: potential chaperones of cytosolic drug transport in the enterocyte?, Pharmaceutical Research [P], vol 28, issue 9, Kluwer Academic/Plenum Publishers, USA, pp. 2176-2190.

Nguyen, T., Hanley, T., Porter, C., Boyd, B., 2011, Nanostructured liquid crystalline particles provide long duration sustained-release effect for a poorly water soluble drug after oral administration, Journal of Controlled Release [P], vol 153, Elsevier, Netherlands, pp. 180-186.

Laguerre, A., Wielens, J., Parker, M., Porter, C., Scanlon, M., 2011, Preparation, crystallization and preliminary X-ray diffraction analysis of two intestinal fatty-acid binding proteins in the presence of 11-(dansylamino)undecanoic acid, Acta Crystallographica Section F: Structural Biology and Crystallization Communications [P], vol 67, issue 2, International Union of Crystallography, United Kingdom, pp. 291-295.

Kaminskas, L., Porter, C., 2011, Targeting the lymphatics using denritic polymers (dendrimers), Advanced Drug Delivery Reviews [P], vol 63, Elsevier Science, Netherlands, pp. 890-900.

Nguyen, T., Hanley, T., Porter, C., Larson, I., Boyd, B., 2010, Phytantriol and glyceryl monooleate cubic liquid crystalline phases as sustained-release oral drug delivery systems for poorly water soluble drugs I. Phase behaviour in physiologically-relevant media, Journal of Pharmacy and Pharmacology [P], vol 62, John Wiley & Sons Ltd., United Kingdom, pp. 844-855.

Nguyen, T., Hanley, T., Porter, C., Larson, I., Boyd, B., 2010, Phytantriol and glyceryl monooleate cubic liquid crystalline phases as sustained-release oral drug delivery systems for poorly water-soluble drugs II. In-vivo evaluation, Journal of Pharmacy and Pharmacology [P], vol 62, issue 7, John Wiley & Sons Ltd., United Kingdom, pp. 856-865.

Trevaskis, N., Charman, W., Porter, C., 2010, Targeted drug delivery to lymphocytes: a route to site-specific immunomodulation?, Molecular Pharmaceutics [P], vol 7, issue 6, American Chemical Society, United States, pp. 2297-2309.

Trevaskis, N., Shanker, R., Charman, W.N., Porter, C.J., 2010, The mechanism of lymphatic access of two cholesteryl ester transfer protein inhibitors (CP524,515 and CP532,623) and evaluation of their impact on lymph lipoprotein profiles, Pharmaceutical Research [P], vol 27, issue 9, Springer, USA, pp. 1949-1964.

Trevaskis, N., McEvoy, C.L., McIntosh, M.P., Edwards, G.A., Shanker, R., Charman, W.N., Porter, C.J., 2010, The role of the intestinal lymphatics in the absorption of two highly lipophilic cholesterol ester transfer protein inhibitors (CP524,515 and CP532,623), Pharmaceutical Research [E], vol 27, Springer Science, USA, pp. 878-893.

Warren, D., Benameur, H., Porter, C.J., Pouton, C.W., 2010, Using polymeric precipitation inhibitors to improve the absorption of poorly water-soluble drugs: A mechanistic basis for utility, Journal Of Drug Targeting [P], vol 18, issue 10, Informa Healthcare, United Kingdom, pp. 704-731.

Velkov, T., Hughes, M.L.R., Horne, H.J., Simpson, J.S., Porter, C.J., Scanlon, M., 2009, Characterization of lipophilic drug binding to rat intestinal fatty acid binding protein, Molecular And Cellular Biochemistry [P], vol 326, issue 1-2, Springer New York LLC, USA, pp. 87-95.

Trevaskis, N., Shackleford, D., Charman, W.N., Edwards, G.A., Gardin, A., Appel-Dingemanse, S., Kretz, O., Galli, B., Porter, C.J., 2009, Intestinal lymphatic transport enhances the post-prandial oral bioavailability of a novel cannabinoid receptor agonist via avoidance of first-pass metabolism, Pharmaceutical Research [P], vol 26, issue 6, Springer New York LLC, USA, pp. 1486-1495.

White, K.L., Nguyen, G., Charman, W.N., Edwards, G.A., Faassen, W.A.(., Porter, C.J., 2009, Lymphatic transport of methylnortestosterone undecanoate (MU) and the bioavailability of methylnortestosterone are highly sensitive to the mass of coadministered lipid after oral administration of MU, Journal Of Pharmacology And Experimental Therapeu..., vol 331, issue 2, American Society for Pharmacology and Experimental Therapeutics, USA, pp. 700-709.

Caliph, S.M., Faassen, W.A., Vogel, G.M., Porter, C.J., 2009, Oral bioavailability assessment and intestinal lymphatic transport of org 45697 and org 46035, two highly lipophilic novel immunomodulator analogues, Current Drug Delivery [P], vol 6, issue 4, Bentham Science Publishers Ltd, The Netherlands, pp. 359-366.

Kaminskas, L.M., Kota, J., McLeod, V.M., Kelly, B.D., Karellas, P., Porter, C.J., 2009, PEGylation of polylysine dendrimers improves absorption and lymphatic targeting following SC administration in rats, Journal of Controlled Release [P], vol 140, issue 2, Elsevier B.V., The Netherlands, pp. 108-116.

Kaminskas, L.M., Wu, Z., Barlow, N., Krippner, G.Y., Porter, C.J.H., 2009, Partly-PEGylated poly-L-lysine dendrimers have reduced plasma stability and circulation times compared with fully PEGylated dendrimers, Journal of Pharmaceutical Sciences [P], vol 98, issue 10, John Wiley & Sons, Inc, USA, pp. 3871-3875.

Kaminskas, L.M., Kelly, B.D., McLeod, V.M., Boyd, B.J., Krippner, G.Y., Williams, E., Porter, C.J., 2009, Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-L-lysine dendrimers, Molecular Pharmaceutics [P], vol 6, issue 4, American Chemical Society, USA, pp. 1190-1204.

Chuang, S., Velkov, T., Horne, H.J., Wielens, J., Chalmers, D.K., Porter, C.J., Scanlon, M., 2009, Probing the fibrate binding specificity of rat liver fatty acid binding protein, Journal of Medicinal Chemistry [P], vol 52, issue 17, American Chemical Society, USA, pp. 5344-5355.

Conference Proceedings

Lee, K.W., Porter, C.J., Boyd, B.J., 2009, Gastric procesing is a critical determinant of the ability of lipid-based formulations to enhance the oral bioavailability of a model poorly water-soluble drug, 36th Annual Meeting & Exposition of the Controlled Release Society, 18/07-22/07/2009, Controlled Release Society, USA, p. on cd.

Boyd, B.J., Nguyen, T., Hanley, T., Porter, C.J., 2009, Non-digestible lipid-based liquid crystalline formulations, even in dispersed submicron form, provide dramatically sustained plasma concentrations for poorly water soluble drugs., 36th Annual Meeting & Exposition of the Controlled Release Society, 18/07-22/07/2009, Controlled Release Society, USA, p. on cd.

Teaching Commitment

  • Biopharmaceutical principles of drug delivery (PAC 4261)
  • Drug delivery system design (PSC 3081)
  • Research project (PAC 3522)

Activities

Affiliations with research centres

Drug Delivery, Disposition and Dynamics
Monash Institute of Pharmaceutical Sciences

Editorships of academic journals

Editorial board member
Journal of Pharmaceutical Sciences

Editorial board member
Journal of Pharmacy and Pharmacology

Editorial board member
Pharmaceutical Research

Grants

Title:
Advanced microscopic facility.
Investigators:
Sexton, P, Bunnett, N, Christopoulos, A, Sloan, E, Canals, M, Lane, J, Summers, R, Porter, C, Halls, M, May, L
Funding:
(2012 - 2016). National Health & Medical Research Council (NHMRC). $30,000.00
(2012 - 2017). National Health & Medical Research Council (NHMRC). $30,000.00
Title:
Capsugel (USA) PG Research S'ship-M.Anby.
Investigators:
Anby, M, Porter, C, Pouton, C
Funding:
(2008 - 2012). Capsugel Division of Pfizer. $0.00
Title:
Designing dendrimer-based lymphatic drug vectors as improved treatments for metastatic cancer.
Investigators:
Porter, C, Kaminskas, L, Boyd, B, Williams, E, Owen, D
Funding:
(2010 - 2014). Australian Research Council (ARC). $410,000.00
(2010 - 2014). Monash University. $25,000.00
(2010 - 2014). Starpharma Pty Ltd. $360,000.00
Title:
Drug Absorption Research Facility.
Investigators:
Charman, W, Charman, S, Porter, C
Funding:
(1999 - 2017). Monash University. $240,000.00
Title:
Drug binding to human fatty acid binding proteins: a mechanism of cellular transport for poorly water soluble drugs.
Investigators:
Porter, C, Scanlon, M
Funding:
(2006 - 2010). Australian Research Council (ARC). $276,000.00
(2006 - 2010). Monash University. $5,000.00
Title:
Engineering pore forming proteins as machines for the delivery of proteins and nanoparticles into cells.
Investigators:
Whisstock, J, Porter, C, Friend, J, Hourigan, K, Boyd, I, Cortez-Jugo, C, Traore, D, Rosado, C
Funding:
(2010 - 2014). Australian Research Council (ARC). $278,400.00
(2010 - 2014). Monash University. $180,000.00
(2010 - 2014). Monash University. $61,281.00
(2010 - 2015). Australian Research Council (ARC). $278,400.00
Title:
Enhanced drug delivery using nanoparticulate dendrimer vectors.
Investigators:
Porter, C, Scammells, P, Krippner, G
Funding:
(2003 - 2007). Australian Research Council (ARC). $135,884.00
(2003 - 2007). Australian Research Council (ARC). $69,098.00
(2003 - 2007). Starpharma Pty Ltd. $186,000.00
Title:
Evaluation of the lymphatic transport of an investigational drug.
Investigators:
Porter, C, Charman, S
Funding:
(1999 - 2003). Pfizer Limited. $55,912.00
Title:
Feasibility study to minimize the food effect of ORG39970 and Andriol.
Investigators:
Porter, C
Funding:
(2004 - 2008). NV Organon. $168,149.00
Title:
Guiding ligands to nuclear receptors: The role of fatty acid binding proteins.
Investigators:
Porter, C, Scanlon, M, Mantamadiotis, T
Funding:
(2009 - 2013). Australian Research Council (ARC). $360,000.00
Title:
Integrating drug delivery principles into drug design to transform the treatment of immune disease.
Investigators:
Porter, C, Charman, W, Alderuccio, F, Trevaskis, N
Funding:
(2011 - 2015). National Health & Medical Research Council (NHMRC). $533,390.00
(2011 - 2016). National Health & Medical Research Council (NHMRC). $0.00
Title:
Intracellular lipid binding proteins as gatekeepers of drug activity.
Investigators:
Porter, C, Scanlon, M, Bunnett, N
Funding:
(2012 - 2016). Australian Research Council (ARC). $410,000.00
(2012 - 2016). Monash University. $111,200.00
Title:
Laser Scanning Confocal Microscope.
Investigators:
Bunnett, N, Sexton, P, Christopoulos, A, Summers, R, Porter, C, Pouton, C, Sloan, E, Lane, J, Canals, M
Funding:
(2011 - 2015). National Health & Medical Research Council (NHMRC). $50,000.00
(2012 - 2016). National Health & Medical Research Council (NHMRC). $50,000.00
Title:
Lipid Formulation Classification System Consortium: Digestion Working Group Program.
Investigators:
Pouton, C, Porter, C
Funding:
(2010 - 2015). Lipid Formulation Classification System Consortium. $278,373.51
Title:
Lymphatic drug transport after fasted oral administration.
Investigators:
Charman, W, Porter, C
Funding:
(2002 - 2006). GlaxoSmithKline, Australia. $137,061.40
Title:
Lymphotropic Prodrugs: A Novel Mechanism for Targeted Drug Delivery.
Investigators:
Porter, C, Charman, W, Stella, V
Funding:
(2011 - 2015). Australian Research Council (ARC). $13,000.00
(2011 - 2015). Australian Research Council (ARC). $450,000.00
(2011 - 2015). Monash University. $8,000.00
Title:
Mechanisms of enhancement of absorption of poorly water-soluble drugs from the gastrointestinal tract mediated by lipids, surfactants and polymers.
Investigators:
Pouton, C, Porter, C, Benameur, H, Hutchison, K
Funding:
(2008 - 2012). Australian Research Council (ARC). $273,120.00
(2008 - 2012). Australian Research Council (ARC). $76,880.00
(2008 - 2012). Capsugel Division of Pfizer. $240,000.00
(2008 - 2012). Monash University. $20,000.00
Title:
Optimising the therapeutic efficacy of protein-based drugs against lymph-resident diseases.
Investigators:
Kaminskas, L, Bulitta, J, Porter, C
Funding:
(2013 - 2017). National Health & Medical Research Council (NHMRC). $336,056.19
Title:
Phenom Benchtop SEM from FEI.
Investigators:
Boyd, B, Nation, R, Pouton, C, Porter, C, Scanlon, M
Funding:
(2009 - 2013). National Health & Medical Research Council (NHMRC). $70,000.00
Title:
Rational Design of Pegylated Dendrimer Nanostructures for Site Specific Drug Delivery.
Investigators:
Porter, C, Boyd, B, Krippner, G
Funding:
(2007 - 2011). Australian Research Council (ARC). $246,428.00
(2007 - 2011). Starpharma Pty Ltd. $335,179.00
Title:
Recognition of macromolecular complexes by cell surface receptors: A novel mechanism of lipid and drug absorption.
Investigators:
Porter, C, Charman, W, Tso, P
Funding:
(2008 - 2011). National Health & Medical Research Council (NHMRC). $377,125.00
(2010 - 2014). National Health & Medical Research Council (NHMRC). $0.00
Title:
Supersaturated and non-digestible dispersions in the intestinal lumen: new mechanisms to reduce variability in the rate and extent of drug absorption.
Investigators:
Pouton, C, Porter, C, Benameur, H
Funding:
(2012 - 2016). Australian Research Council (ARC). $330,000.00
(2012 - 2016). Australian Research Council (ARC). $42,000.00
(2012 - 2016). Capsugel France SAS. $300,000.00
(2012 - 2016). Capsugel France SAS. $67,500.00
Title:
The design of functional antagonists of the S1P, modulators with selective exposure to lymphatic tissue through directed gastro-intestinal uptake.
Investigators:
Flynn, B, Porter, C, Sexton, P
Funding:
(2011 - 2015). Multiple Sclerosis Research Australia. $25,000.00
Title:
The role of fatty acid binding proteins in the binding and transport of lipophilic drugs.
Investigators:
Scanlon, M, Porter, C
Funding:
(2003 - 2009). Australian Research Council (ARC). $255,000.00
Title:
Advanced Fluorescence Imaging Facility: From Super High Resolution to Whole Animal Imaging.
Investigators:
Porter, C, Caruso, F, Heath, W, Nation, R, Prawer, S, Wijburg, O, Pouton, C, Johnston, A, Sloan, E, Kaminskas, L, Shepherd, R
Funding:
(2011 - 2015). Australian Research Council (ARC). $0.00
(2011 - 2015). Monash University. -$100,000.00
(2011 - 2015). Monash University. -$205,000.00

Postgraduate Research Supervisions

Current Supervision

Program of Study:
(DOCTORATE BY RESEARCH).
Thesis Title:
Decreased brain levels of essential fatty acids in Alzheimer's disease: the role of the BBB.
Supervisors:
Nicolazzo, J (Main), Porter, C (Associate), Scanlon, M (Associate).
Program of Study:
(DOCTORATE BY RESEARCH).
Thesis Title:
Do intracellular binding proteins facilitate drug absorption and drug targeting to the nucleus?.
Supervisors:
Porter, C (Joint), Scanlon, M (Joint-co).
Program of Study:
(DOCTORATE BY RESEARCH).
Thesis Title:
Drug delirem/drug targeting to lumocytes via the intestional lymph.
Supervisors:
Porter, C (Main), Trevaskis, N (Associate).
Program of Study:
(DOCTORATE BY RESEARCH).
Thesis Title:
Fatty acid binding protein at BBB: a novel taget for enhancing DHA in Alzeimer's disease?.
Supervisors:
Nicolazzo, J (Main), Porter, C (Associate), Scanlon, M (Associate).
Program of Study:
(DOCTORATE BY RESEARCH).
Thesis Title:
Improving chemotherapeutic efficancy against lymphatic metastases via the selective lymphatic delivery of chemotherapeutic nanomedicines.
Supervisors:
Porter, C (Main), Kaminskas, L (Associate), Mcintosh, M (Associate).
Program of Study:
(DOCTORATE BY RESEARCH).
Thesis Title:
Ionic liquids as potential drug delivery vehicles.
Supervisors:
Scammells, P (Main), Porter, C (Associate).
Program of Study:
(DOCTORATE BY RESEARCH).
Thesis Title:
Molecular dynamics simulations of lipid drug delivery systems.
Supervisors:
Chalmers, D (Joint), Pouton, C (Joint-co), Porter, C (Associate).
Program of Study:
(DOCTORATE BY RESEARCH).
Thesis Title:
New polymers for MRI applications.
Supervisors:
Porter, C (Main).
Program of Study:
(DOCTORATE BY RESEARCH).
Thesis Title:
Non-digestible & digestion-modulating lipid-based drug delivery systems..
Supervisors:
Porter, C (Main).
Program of Study:
(DOCTORATE BY RESEARCH).
Thesis Title:
Thrombin-activatable -plasminogen fusion proteins for the treatment of acute thrombosis.
Supervisors:
Hagemeyer, C (Joint), Porter, C (Joint-co).
Program of Study:
(DOCTORATE BY RESEARCH).
Thesis Title:
Using lipid based formulations to enhance drug exposure.
Supervisors:
Porter, C (Joint-co), Pouton, C (Associate), Williams, H (Associate).

Completed Supervision

Student:
Caliph, S.
Program of Study:
AN INVESTIGATION OF THE IMPACT OF LIPIDIC FORMULATIONS ON THE LYMPHATIC TRANSPORT AND ORAL BIOAVAILABILITY OF HALOFANTRINE. (Masters) 2001.
Supervisors:
Porter, C (Main), Charman, W (Associate).
Student:
Chuang, S.
Program of Study:
The interactions of rat liver fatty acid binding protein with drug molecules. (PHD) 2008.
Supervisors:
Porter, C (Joint), Scanlon, M (Joint-Co).
Student:
Cuine, J.
Program of Study:
In vitro - in vivo evaluation of self-emulsifying lipid-based formulations for the oral administration of poorly water-soluble drugs. (PHD) 2007.
Supervisors:
Charman, W (Joint-Co), Porter, C (Joint).
Student:
Johnson, B.
Program of Study:
INTESTINAL EFFLUX AND METABOLISM PROCESSES AS BIOCHEMICAL BARRIERS TO ORAL DRUG ABSORPTION. (PHD) 2003.
Supervisors:
Porter, C (Main), Charman, W (Associate).
Student:
Karellas, P.
Program of Study:
Synthesis of novel bivalent and multivalent ligands targeting the beta2 adrenergic and A1 adenosine receptor and the synthesis of functionalised poly-L-lysine dendrimers. (PHD) 2011.
Supervisors:
Scammells, P (Main), Porter, C (Associate).
Student:
Katneni, K.
Program of Study:
The impact of solubilising agents on the in vitro assessment of intestinal drug permeability and transporter function. (PHD) 2006.
Supervisors:
Charman, S (Joint-Co), Porter, C (Joint).
Student:
Kossena, G.
Program of Study:
Assessing the phase behaviour, solubilisation and bioavailability enhancement provided by the digestion products of commonly used formulation lipids. (PHD) 2005.
Supervisors:
Porter, C (Main), Charman, W (Associate), Boyd, B (Associate).
Student:
Kota, J.
Program of Study:
The impact of injection site and animal model on the lymphatic absorption of subcutaneously administered proteins. (PHD) 2007.
Supervisors:
Charman, S (Joint-Co), Porter, C (Joint).
Student:
Laguerre, A.
Program of Study:
Characterising the drug binding sites of human intestinal and liver fatty acid binding proteins. (PHD) 2009.
Supervisors:
Porter, C (Joint-Co), Scanlon, M (Joint).
Student:
Lee, Y.
Program of Study:
THE ROLE OF THE ACIDIC MICROCLIMATE IN THE ABSORPTION OF LIPOPHILIC DRUGS FROM INTESTINAL MIXED MICELLES. (Masters) 2001.
Supervisors:
Porter, C (Main), Charman, W (Associate).
Student:
Mclennan ((Double Id)), D.
Program of Study:
THE CONTRIBUTION OF THE LYMPHATICS TO THE SYSTEMIC AVAILABILITY OF SUBCUTANEOUSLY ADMINISTERED RECOMBINANT PROTEINS. (PHD) 2004.
Supervisors:
Charman, S (Main), Porter, C (Associate).
Student:
Mclennan, D.
Program of Study:
THE CONTRIBUTION OF THE LYMPHATICS TO THE SYSTEMATIC AVAILABILITY OF SUBCUTANEOUSLY ADMINISTERED RECOMBINANT PROTEINS. (PHD) 2004.
Supervisors:
Charman, S (Main), Porter, C (Associate).
Student:
Nguyen, T.
Program of Study:
Investigation of novel liquid crystalline materials for the sustained oral delivery of poorly water soluble drugs. (PHD) 2008.
Supervisors:
Boyd, B (Main), Larson, I (Associate), Porter, C (Associate).
Student:
Segrave, A.
Program of Study:
AN INVESTIGATION OF THE PHARMACOKINETICS AND LYMPHATIC TRANSPORT OF RECOMBINANT HUMAN LEUKAEMIA INHIBITORY FACTOR. (PHD) 2004.
Supervisors:
Charman, S (Joint-Co), Porter, C (Joint).
Student:
Sek, L.
Program of Study:
AN IN VITRO MODEL OF LIPID DIGESTION FOR ASSESSING THE ORAL BIOAVAILABILITY ENHANCEMENT POTENTIAL OF LIPIDIC FORMULATIONS. (PHD) 2003.
Supervisors:
Charman, W (Main), Porter, C (Associate).
Student:
Trevaskis, N.
Program of Study:
An examination of biological factors which influence intestinal lymphatic drug transport in the rat. (PHD) 2005.
Supervisors:
Charman, W (Joint-Co), Porter, C (Joint).